Quarti-Trevano Fosca, Dell'Oro Raffaella, Cuspidi Cesare, Ambrosino Pasquale, Grassi Guido
Clinica Medica, School of Medicine and Surgery, University Milano-Bicocca, 20052 Monza, Italy.
Istituti Clinici Scientifici Maugeri IRCCS, Directorate of Telese Terme Institute, 82037 Telese Terme, Italy.
Biomedicines. 2023 Mar 6;11(3):803. doi: 10.3390/biomedicines11030803.
Vascular and sympathetic abnormalities characterize chronic heart failure (CHF). Alterations include (1) a reduction in arterial distensibility, (2) endothelial dysfunction, (3) a decrease in arterial compliance and a parallel increase in arterial stiffness, and (4) sympathetic cardiovascular activation. Altogether, these alterations represent important targets in therapeutic interventions, because they display an independent negative impact on the disease prognosis, favouring disease progression and the development of cardiovascular complications with direct and indirect mechanisms. The present review will examine the effects of the different therapeutic interventions targeting the vascular/sympathetic alterations detected in CHF. Non-pharmacological, pharmacological and device-based treatments will be discussed in detail, highlighting the possible mechanisms responsible for the vascular/sympathetic effects of each intervention. Finally, the unmet goals in treatment in relation to endothelial and adrenergic targets will be also discussed.
血管和交感神经异常是慢性心力衰竭(CHF)的特征。这些改变包括:(1)动脉扩张性降低;(2)内皮功能障碍;(3)动脉顺应性降低以及动脉僵硬度相应增加;(4)交感神经对心血管系统的激活。总体而言,这些改变是治疗干预的重要靶点,因为它们对疾病预后具有独立的负面影响,通过直接和间接机制促进疾病进展以及心血管并发症的发生。本综述将探讨针对CHF中检测到的血管/交感神经改变的不同治疗干预措施的效果。将详细讨论非药物治疗、药物治疗和基于器械的治疗,突出每种干预措施产生血管/交感神经效应的可能机制。最后,还将讨论在内皮和肾上腺素能靶点治疗方面尚未实现的目标。